Long-term study of Sogroya for children with growth hormone deficiency
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial is looking at how well Sogroya® (a growth hormone medicine) works when used for a long time in children with short stature caused by growth hormone deficiency. The goal is to see if it helps them grow taller safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a child between 0 and 18 years old (before your 18th birthday).
- You have been diagnosed with short stature caused by growth hormone deficiency, and your growth plates (the areas at the ends of your bones that allow you to grow taller) are still open.
- You and your doctor have already decided to use Sogroya® (a medicine for growth hormone deficiency) before being asked to join this study.
- You cannot be enrolled if you have already taken part in this same study before.
- You cannot have taken any other experimental drug in the past 30 days.
- You cannot have a history of cancer, be pregnant, or be allergic to any ingredient in Sogroya®.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new growth hormone medicine (GB06) for children whose bodies don't make enough growth hormone naturally. The study will see if this treatment helps children grow taller over time.
This study follows adults with growth hormone deficiency who start (or have started) Sogroya to learn about its long-term safety. It does not change your treatment—it mainly checks for side effects and health outcomes over time.
This study looks at how well somatrogon works for children 3 years and older with growth hormone deficiency. It may help you understand if this treatment is an option for your child.
This study is watching children who are already taking somapacitan (a growth hormone injection) to see if it is safe over a long time. It collects information about growth and any side effects.
This study tracks the safety of lonapegsomatropin in children being treated for growth hormone deficiency (GHD). It’s meant to check for side effects and make sure the medicine continues to be safe in real-world use.
This trial tests an oral medication called GS3-007a for children who have not yet reached puberty and have growth hormone deficiency. The goal is to see if it helps them grow taller.
Hear when a new Growth Hormone Deficiency in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.